Height velocity and its relation with serum ferritin and pretransfusion haemoglobin in thalassemia patients: results from a tertiary center in Northeast India
DOI:
https://doi.org/10.18203/2349-3291.ijcp20223061Keywords:
Height velocity, Thalassemia, Serum ferritinAbstract
Background: ẞ-thalassemia syndromes are the commonest single gene disorders in the Indian population and growth failure remains a major concern among these patients.
Methods: We studied the relation of height velocity with serum ferritin and pretransfusion hemoglobin in 30 transfusion dependent thalassemia patients aged 1-12 years attending our centre. The height measurements were taken every 6 months for one year. Serum ferritin was measured 3 monthly and pretransfusion hemoglobin was measured at each visit.
Results: The prevalence of impaired height velocity in transfusion dependent thalassemics in our study was 56.67%. The mean pretransfusion hemoglobin was 7.8±1.065 g/dl and the mean serum ferritin level in our study was 2426±872 ng/ml. In thalassemia patients with height velocity < 3rd percentile mean serum ferritin level was 2637±892.84 ng/ml while the mean serum ferritin level in patients with height velocity >3rd percentile was 1875±564.007 ng/ml with a statistically significant relation (p=0.012). Although the mean pretransfusion hemoglobin in children with height velocity <3rd percentile was found to be lower compared to their counterparts with height velocity >3rd percentile (7.42±0.879 g/dl vs. 7.96±0.998 g/dl), this relation was found to be statistically insignificant (p value=0.127).
Conclusions: Our study highlights that even though regular blood transfusions are essential in thalassemic patients, maintaining an optimal ferritin level is equally essential in influencing growth in these children.
References
Smith-Whitley K, Kwiatkowski JL. Hemoglobinopathies. In: Kliegman RM, ST Geme J, Blum N, Tasker RC, Shah SS, Wilson KM, eds. Nelson Textbook of Pediatrics. 21st ed. Philadelphia: Elsevier; 2019:2540-54.
Badiger S, Baruah A. A study of growth pattern in regularly transfused thalassaemic children of age group of 2 years to 12 years. Int J Contemp Pediatr. 2019;6(4):1575.
Nokeaingtong K, Charoenkwan P, Silvilairat S, Saekho S, Pongprot Y, Dejkhamron P. A longitudinal study of growth and relation with anemia and iron overload in pediatric patients with transfusion-dependent thalassemia. J Pediatr Hematol Oncol. 2016;38(6):457-62.
Moiz B, Habib A, Sawani S, Raheem A, Hasan B. Anthropometric measurements in children having transfusion-dependent beta thalassemia. Hematology. 2018;23(4):248-52.
Pemde HK, Chandra J, Gupta D, Singh V, Sharma R, Dutta A. Physical growth in children with transfusion-dependent thalassemia. Pediatr Heal Ther. 2011;2:13-9.
Mishra AK, Tiwari A. Iron overload in Beta thalassaemia major and intermedia patients. Maedica. 2013;8(4):328-32.
Riaz H, Riaz T, Khan MU, Aziz S, Ullah F, Rehman A, et al. Serum ferritin levels, socio-demographic factors and desferrioxamine therapy in multi-transfused thalassemia major patients at a government tertiary care hospital of Karachi, Pakistan. BMC Res Notes. 2011;4(1):287.
Alias H, Latiff ZA, Zulkifli S, Zakaria S, Jamal R. Growth velocity in transfusion dependent prepubertal thalassemia patients: Results from a thalassemia center in Malaysia. Southeast Asian J Trop Med Public Health. 2008;39(5):900-5.
Soliman AT, ElZalabany M, Amer M, Ansari BM. Growth and pubertal development in transfusion-dependent children and adolescents with thalassaemia major and sickle cell disease: A comparative study. J Trop Pediatr. 1999;45(1):23-30.
